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A B S T R A C T
Background and objectives: Quantitative MRI (qMRI) permits the quantification of brain changes compatible with
inflammation, degeneration and repair in multiple sclerosis (MS) patients. In this study, we propose a new
method to provide personalized maps of tissue alterations and longitudinal brain changes based on different
qMRI metrics, which provide complementary information about brain pathology.
Methods: We performed baseline and two-years follow-up on (i) 13 relapsing-remitting MS patients and (ii) four
healthy controls. A group consisting of up to 65 healthy controls was used to compute the reference distribution
of qMRI metrics in healthy tissue. All subjects underwent 3T MRI examinations including T1, T2, T2* relaxation
and Magnetization Transfer Ratio (MTR) imaging. We used a recent partial volume estimation algorithm to
estimate the concentration of different brain tissue types on T1 maps; then, we computed a deviation map (z-
score map) for each contrast at both time-points. Finally, we subtracted those deviation maps only for voxels
showing a significant difference with healthy tissue in one of the time points, to obtain a difference map for each
subject.
Results and conclusion: Control subjects did not show any significant z-score deviations or longitudinal z-score
changes. On the other hand, MS patients showed brain regions with cross-sectional and longitudinal concomitant
increase in T1, T2, T2* z-scores and decrease of MTR z-scores, suggesting brain tissue degeneration/loss. In the
lesion periphery, we observed areas with cross-sectional and longitudinal decreased T1/T2 and slight decrease in
T2* most likely related to iron accumulation. Moreover, we measured longitudinal decrease in T1, T2 - and to a
lesser extent in T2* - as well as a concomitant increase in MTR, suggesting remyelination/repair.
In summary, we have developed a method that provides whole-brain personalized maps of cross-sectional and
longitudinal changes in MS patients, which are computed in patient space. These maps may open new per-
spectives to complement and support radiological evaluation of brain damage for a given patient.
1. Introduction
Neuroinflammatory and neurodegenerative diseases induce variable
damage to the central nervous system, which can be quantified using
magnetic resonance imaging (MRI). New advanced MRI techniques
exhibit a level of sensitivity and specificity to focal and diffuse pa-
thology that are not available through conventional MRI (Enzinger
et al., 2015). Relaxometry and magnetization transfer imaging (MTI),
for example, provide measures of biophysical parameters that show
different sensitivity to the amount of free water, the amount of water
bound to micro- and macromolecules and the amount of paramagnetic
substances (i.e. iron), for review see (Helms, 2015). The combination of
these MRI contrasts are sensitive and specific to the consequences of
neuroinflammation and neurodegeneration, thus they are invaluable
assets to perform disease diagnosis and monitoring.
Recent advances in qMRI mainly focus on how to accelerate (Bilgic
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et al., 2015; Hilbert et al., 2018; Metere et al., 2017; Sumpf et al., 2011)
and to standardize (Deoni et al., 2008; Droby et al., 2015; Helms, 2015)
qMRI acquisitions, in order to improve their translation into clinical
applications. Yet, how to perform individual evaluation of qMRI
changes remains an open question.
In contrast to studies based on the comparison between groups,
single-subject predictions (i.e. the classification of one subject as being
part of one of the groups of the study, e.g. healthy vs. patient) are
challenging and prone to the biases induced by the analysis method and
the bias inherent to the data, which is increased in subjects with neu-
rological pathologies (Arbabshirani et al., 2017).
In recent years, machine-learning based methods have been pro-
posed to classify patients with pathology and healthy subjects, which
provide the probability of a dataset to belong to either one of the ca-
tegories. Yet, these approaches suffer from the intrinsic limitations re-
lated to (i) how feature selection is performed to differentiate the tar-
geted classes (i.e. classical machine methods) and/or (ii) the risk of
overfitting when very complex models are applied to relatively small
amount of data (classical and modern machine learning methods,
(Arbabshirani et al., 2017; Meyer et al., 2017; Stephan et al., 2017).
A more traditional approach to compare single-patient data to a
cohort of healthy individuals is based on a voxel basis by using voxel-
based morphometry (VBM) analysis (Beeson et al., 2011; Colliot et al.,
2006; Kruggel et al., 2017; Muhlau et al., 2009; Sajjadi et al., 2013).
Voxel-based methods rely on the non-rigid registration of the patient
brain volume to a group of healthy control volumes in a common space
prior to the voxel-wise comparison. The non-rigid registration can be
then combined with a deformation field, which is encoded for each
subject as tissue density changes in the normal space.
Despite the undeniable utility of voxel-based methods, they suffer
from important limitations arising from (i) the large topological struc-
tural differences among individual brains, (ii) the necessary averaging
resulting in image blurring introduced to achieve noise reduction and
spatial coherence – and (iii) partial volume effects (PVE). PVE occurs
when an imaging voxel contains more that one tissue type, yielding a
signal equal to the weighted average of its components. The main ca-
veat is that in regions with spatially varying intensities such as edge
structures, the aforementioned effects can shift the apparent position of
abnormalities detected by several voxels (Bookstein, 2001). Moreover,
the interpretation of the results using single-to-group VBM analysis is
problematic; especially if we consider that any statistical difference
between a single subject and a group might either just reflect individual
variability in neuroanatomy (instead of any alteration due to the dis-
ease under study) or designate a false positive as result of the data being
sampled from a non-normally distributed population (Scarpazza et al.,
2013).
In this study, we propose a new method to perform an individual
analysis of qMRI maps that provides complementary information about
changes in brain tissue on a single-subject basis. Different than voxel-
based methods, our methodology allows a voxel-wise comparison in the
subject space without the need of inter-patient registration. In short, for
a given voxel in a qMRI map, we compare its scalar value with the
distribution of the voxels belonging to the same tissue class and region
in a group of healthy subjects and provide deviation maps from its
“normative” range. To assess our method and its ability to detect subtle
microstructural pathological changes within the brain, we applied our
approach to a longitudinal multi-contrast dataset of relapsing-remitting
multiple sclerosis (RRMS) patients, which included T1, T2, T2* re-
laxometry and magnetization transfer imaging.
2. Methods
2.1. Population
Fifteen (15) RRMS patients (10 women/5 men, age=32 ± 4 years
[mean ± standard deviation-SD], month since diagnosis= 33 ± 22
[mean ± SD], EDSS= 1.5 [1–2] [median [range]]) diagnosed using
the revised McDonald criteria (Polman et al., 2011) and twenty (20)
healthy controls (HC) (12 women/8 men, age= 31 ± 7 years) were
enrolled at the Lausanne University Hospital (CHUV), Lausanne, Swit-
zerland. A larger cohort of 65 healthy controls was used as a reference
for qT1 maps, which were acquired at the CHUV in the context of an-
other study, with the same protocol and in the same scanner applied for
the current study (see Table 1).
Inclusion criteria were: RRMS diagnosis and less than five year
disease duration from diagnosis; for HC: absence of previous neurolo-
gical and psychiatric disease, no history of smoke and alcohol abuse and
no current medication. Patients were followed up at two years
(21.9 ± 2months). At study enrollment, no patient had received cor-
ticosteroid therapy for at least three months. Immunomodulatory
treatment consisted of high dosage of either interferon beta or fingo-
limod. Fingolimod is used as a first line therapy in Switzerland.
The ethics committee of the Lausanne University Hospital (CHUV)
approved the study and all the participants gave written informed
consent.
After preprocessing and qualitative evaluation of acquired MR
images, 2 RRMS subjects were excluded due to motion, distortion and
other artifacts seen in at least one of the contrasts used in the study (see
Table 1).
The baseline and longitudinal personalized maps were computed for
the 13 RRMS patients and four healthy subjects (2 women/2 men; age
34.5 ± 7.5 years), who were randomly chosen out of the control group
(HC).
The healthy distribution (HD) of each contrast's parametric map
used for reference was computed from the remaining 16 healthy con-
trols (10 women/6 men; age 32 ± 10 years). An additional healthy
distribution from 65 controls (42 women/23 men; age
51.68 ± 3.46 years) was used to calculate a reference for qT1 maps as
stated above (HD2, Table 1). The four healthy subjects selected as a
control test group for the computation of the personalized deviation
map were not part of the group of controls used to calculate the healthy
distribution.
2.2. Image acquisition and reconstruction
All subjects underwent MRI examinations in a 3T Magnetom Trio
(Siemens Healthcare, Erlangen, Germany) using the following protocol:
(1) High-resolution magnetization-prepared acquisition with gradient
echo (MPRAGE); (2) 3D fluid attenuated inversion recovery (3D
FLAIR); (3) 3D double inversion recovery (3D DIR); (4) Magnetization-
Table 1
Characteristics of the study participants. Data are presented as mean (standard deviation) for continuous variables and count for categorical variables. NA stands for
not applicable. Lesion load corresponds to the percentage of the total lesion volume over the total intracranial volume (TIV).
RRMS (n=15) HC (n=4) HD (n=16) HD2 (n=65)
Age [years] 32 (4.6) 34.5 (7.5) 32.5 (10) 51.68 (3.46)
Gender (male/female) 5/10 2/2 6/10 23/42
Time since diagnosis [months] 33.2 (22.4) NA NA NA
Time since first relapse [months] 33.5 (25.8) NA NA NA
Lesion load [%] 0.55 (0.6) NA NA NA
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Prepared 2 Rapid Acquisition Gradient Echoes MP2RAGE (Marques
et al., 2010) for lesion identification and T1 relaxometry maps; (5) T2*
relaxation using a prototype Gradient-Recalled-Echo (GRE) sequence
with and without magnetization transfer (MT) preparation pulse (flip-
angle 220°, duration=4000ms; pulse offset= 2000 Hz; spoiler mo-
ment 25,000 μs×mT/m (Helms and Hagberg, 2009)). MTR maps were
derived from the T2* data using the following formula:
=MTR M M
M
T0
0
With M0 and MT the images acquired without and with MT pulse, re-
spectively. MTR was computed for each echo and averaged over all
echoes. Finally, (6) T2 relaxation obtained using a prototype 2D Carr-
Purcell-Meiboom-Gill (CPMG) sequence with a nonlinear inverse re-
construction algorithm that directly estimates a T2 and spin-density
map from a train of undersampled spin echoes (Sumpf et al., 2011). The
acquisition of T2 relaxometry maps was performed with a lower spatial
resolution than the one achieved for the other MRI contrasts.
Sequence's parameters are summarized in Table 2. Visual inspection
of image quality was performed in all cases.
2.3. Personalized qMRI analysis
The proposed method relies on a voxel-to-region comparison, cal-
culating a deviation score (i.e. a z-score) between (i) the MR metric of
the input image in each voxel and (ii) the MR metric distribution of the
corresponding healthy tissue of the same brain region. To test the
sensitivity of each parametric map to detect neuroinflammatory or
neurodegenerative processes, the personalized maps were computed
over the T1, T2 and T2* relaxation and MTR maps.
The condition that should be fulfilled to minimize biases is that at
least one contrast should provide sufficient detailed structural in-
formation in order to quantify the concentration of each brain tissue-
type, which is done to minimize PVE.
The overall methodology can be summarized as follows:
(1) data preprocessing.
(2) brain segmentation into white matter (WM), gray matter (GM),
cerebrospinal fluid (CSF) and a segmentation into four main lobes
and deep gray matter nuclei (DGMN);
(3) tissue concentration's estimation for partial volume correction and
tissue's intensity characterization at each voxel;
(4) segmentation and identification of lesions as WM, GM or mixed
lesions;
(5) computation of the data statistics (mean, variances and co-var-
iances) of the healthy tissue intensity distribution for each tissue
and region of interest;
(6) computation of the deviation score for each voxel in the patient
MRI based on the healthy tissue distribution previously calculated,
for each qMRI contrast.
Steps (2) and (3) were computed using only the uniform (UNI)
image from MP2RAGE. Step (4) was computed on the UNI (MP2RAGE),
3D FLAIR and DIR contrasts. An additional affine transformation to UNI
image was added for the T2, T2* and MTR contrasts in order to map
segmentation masks and tissue concentration maps (the masks and
tissue concentration maps were computed only over the T1 maps, since
they are more sensitive to differences between brain tissue types than
other maps; see Section 2.3.2).
All data outputs were inspected at all processing steps to assure the
accuracy of volume estimation, alignment of multi-modal MRI and fu-
sion with lesion maps. Note that no registration is needed if only one
contrast is used and the tissue characterization using the PVE is done
over the same contrast. The following paragraphs provide a compre-
hensive description of these steps.
2.3.1. Data preprocessing
UNI MP2RAGE images were skull-stripped using the Morphobox
prototype (see next section). T2* and MTR MR scans were corrected for
gradient distortions and B1 inhomogeneities
2.3.2. Brain segmentation
Tissue segmentation was performed over the UNI MP2RAGE image
(in patient space) using the Morphobox prototype, a software based on
variational expectation-maximization tissue classification (Roche et al.,
2014; Schmitter et al., 2015). The same algorithm parcellated the brain
in four main lobes: parietal, frontal, occipital and temporal (from now
our regions-of-interest, ROIs), as well as the DGMN (thalamus, caudate,
putamen and globus pallidus, see Supplementary Information section,
SI.1, for an example of ROIs segmentation).
2.3.3. Tissue concentration estimation for partial volume correction
In many brain regions, especially at the border between different
brain tissues, MRI intensities suffer from the so-called PVE, i.e. the
imaging voxels contains more than one tissue type, yielding a signal
equal to the weighted average of its components. To account for this
effect in our analysis, we estimated the concentration of GM, WM and
CSF in each of these neighboring voxels, assigning value computed as a
mixture of tissues instead of assigning them a single tissue type. This
was done by applying a PVE algorithm that was proposed by Roche and
Forbes (Roche et al., 2014), which relies on continuous Markov
Random Field (MRF) models, with the tissue concentration estimation
formulated as a Bayesian maximum a posterior (MAP). This algorithm
specifically uses a model that describes the intensity of each voxel (y) as
the sum of GM, WM and CSF characteristic intensities in a given region,
weighted by their respective local concentrations, with additive Gaus-
sian noise:= + + + =y C µ C µ C µ with N µ, (0, )GM GM WM WM CSF CSF
where μGM, μWM, μCSF are the characteristic intensities of each tissue and
CGM, CWM, CCSF are the concentrations of GM, WM, and CSF respec-
tively. ε is the additive Gaussian noise (with zero mean and σ standard
deviation).
In order to solve this ill-posed problem, we set three hyper-para-
meters to regularize the following assumptions on brain tissue in-
tensities: (i) voxels with mild partial volume are more frequent than
those with strong partial volume; (ii) tissue concentration maps are
spatially smooth; and (iii) mean tissue intensities are bounded (see SI.2
Table 2
MRI protocol. TR: Repetition time [ms]; TE: Echo time [ms]; TI: Inversion time [ms]; FoV [mm]; Field of view [mm3]; TA [min:sec]; Acquisition time; Misc. stands for
parameters specific to a sequence.
TR/TE Voxel size FoV TA Misc
MPRAGE 2300/2.98 1.0×1.0×1.2 256×240×192 5:12 GRAPPA factor= 2
3D FLAIR 5000/394 1.0×1.0×1.2 256×240×212 6:27 TI= 1800
3D DIR 10,000/218 1.1×1.2×1.2 256×240×192 12:52 TI1/TI2= 450/3652
MP2RAGE 5000/2.89 1× 1×1.2 256×240×212 8:22 TI1/TI2= 700/2500
CMPG 5850/9 1×1×4 210×175×120 3 21 echoes - 30 slices
GRE 47/1.23 1.6×1.6×1.6 217×217×179 11:16 32 gradient echoes w/wo MT
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section for more details).
The algorithm proceeds iteratively until convergence. Once the
characteristic intensities μGM, μWM, μCSF are initialized, the algorithm
estimates the tissue concentrations CGM, CWM, CCSF (step 1) and the
characteristic intensities μGM, μWM, μCSF (step 2) as well as the noise
standard deviation, σ. These steps are repeated until the cost function of
Fig. 1. Example of WM and GM concentration maps
(cmaps) as computed from an exemplary T1 map.
From left to right, top row (A): original white matter
(WM) cmap in axial, sagittal and coronal view;
middle row (B), original gray matter (GM) cmap in
axial, sagittal and coronal view. On the bottom row
(C), example of a WM cmap correction. From left to
right, original WM cmap and corrected cmap.
Fig. 2. Processing pipeline for the computation of the deviation map for the T1, T2, T2* and MTR acquisitions.
G. Bonnier et al. NeuroImage: Clinical 21 (2019) 101607
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the algorithm converges below a defined threshold (see SI, for summary
description of the PVE method). The algorithm outputs three con-
centration maps, one for each tissue (GM, WM and CSF) and the
characteristic intensity values for GM, WM and CSF (see Fig. 1A and B
for WM and GM concentration maps [cmap] examples).
Since T1 maps are more sensitive to differences between brain tissue
types than other maps, we performed the tissue concentration estima-
tion on quantitative T1 maps: we initialized the mean intensities at
1350ms for the GM and 850ms for WM, which are the characteristic
mean relaxation times according to (Marques et al., 2010). In addition,
we applied the algorithm on each ROI separately to consider the
variability of T1 signal over the brain (see Section 2.3.6.). We then
registered the T2, T2* and MTR maps to the subjects' T1 map space
(intra-subject registration) to use tissue concentrations maps estimated
from the T1 contrast. To do this, we estimated an affine transformation
from the T2 and T2* map space (which is the same than the MTR space)
to the T1 map space using Elastix c++ library (Klein et al., 2010).
2.3.4. Lesion segmentation and lesion tissue identification
Brain lesions were manually counted by consensus between an ex-
pert neurologist and radiologist the in the 3DFLAIR, DIR and MP2RAGE
uniform images as previously performed (Bonnier et al., 2014; Bonnier
et al., 2015; Kober et al., 2012; Romascano et al., 2015). A trained
technician generated manual contours for each lesion in the three
Fig. 3. Error bar plots for T1 mean z-score in (A) NAWM in the RRMS patients (blue bars) and HC WM (red bars) and in (B) lesions (red bars), lesion surroundings
(green) and NAWM (blue) in RRMS patients. Whisker extends to the most extreme data points. (For interpretation of the references to color in this figure legend, the
reader is referred to the web version of this article.)
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different contrasts. In order to maximize the sensitivity of lesion count
and volume, the masks of segmented lesions in each contrast (3D
FLAIR, DIR and MP2RAGE) were then merged in a single “union lesion
mask” as in (Bonnier et al., 2014; Bonnier et al., 2015; Kober et al.,
2012; Romascano et al., 2015). Lesion volumes were computed and
normalized by total intracranial volume as obtained using an in-house
software and classified as WM, GM or mixed lesions. The lesion union
mask and the ROIs masks were then registered to the T1, T2, T2*, and
MTR maps.
The method used to estimate tissue concentration is robust to subtle
signal intensity variations, but fails when tissue damage drastically
changes MR signal like in brain lesions and their vicinity. In that case,
the algorithm identifies altered WM as a mix of WM and GM (or even
CSF). Thus, we a posteriori modified the concentration maps inside
brain lesions, based on a single hypothesis: there is no GM inside WM.
Specifically, we attributed (i) 100% WM concentration to a voxel
belonging to a pure WM lesion, (ii) 100% GM concentration to a voxel
belonging to a GM lesion and (iii) 50% WM and 50% GM concentration
to a voxel belonging to a mixed WM-GM lesion. While in our work
lesions were manually segmented, we have also integrated a software
for automated lesion detection in the pipeline (Fartaria MJ, 2017a, b).
Additionally, we performed morphological operations on the white
matter concentration map to apply the a-priori knowledge that there is
no GM in the WM: first, we binarized the WM concentration map by
thresholding it (we use a high threshold in order to keep voxels with
partial volume (GM/WM border) out of the process). Then we filled the
holes inside the WM binary map and finally combine the binary map
with original WM concentration map (see Fig. 1C).
2.3.5. Computation of healthy tissue distribution for each qMRI map
T1, T2, T2* and MTR metrics vary depending on the underlying
microstructure in the subjects and therefore exhibit different values
Fig. 4. Axial view of one T1 z-score map of five RRMS patients (top row) and the four healthy controls (bottom row).
Fig. 5. Axial (top) and sagittal (bottom) view of a T1 z-score map (over the corresponding T1 map) in control 1 (A) and patients 1 and 5, who exhibit high lesion load
(B). (C) The zoomed area from patient's maps shows a diffuse pattern between the lesions.
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across the brain (Aubert-Broche et al., 2009; Wansapura et al., 1999).
However, these parameters are considered relatively homogeneous
within each cerebral lobe (Georgiades et al., 2001; Hasan et al., 2012).
For each qMRI contrast, we estimated a healthy tissue distribution
for each brain lobe (frontal, parietal, occipital and temporal). We used a
cohort of 65 healthy controls to compute the reference healthy tissue
distribution for the T1 parametric maps and 15 controls for the other
parametric maps in each brain tissue (WM, GM, and CSF) and ROI.
For each control, we first segmented the brain into WM, GM and
CSF tissues as well as in four different lobes (ROIs) (Section 2.3.1) and
then estimated their tissue concentrations separately (Section 2.3.2).
For each control subject and ROI, only voxels with at least 95%
concentration of the same tissue (WM or GM) were considered. To es-
timate the data's statistics (mean, standard deviation and covariances)
considering intra- and inter-subjects variability, for each ROI we per-
formed a bootstrapping analysis on the entire healthy controls cohort.
In this context, we consider the data statistics (mean and standard de-
viation values) derived from the healthy distribution as being reason-
ably representative of the distribution, so that the z-score (used as a
measure of deviation) shows abnormal brain tissue microstructure (see
SI.3).
2.3.6. Deviation maps
The personalized deviation maps were computed by comparing the
intensity of a single voxel in the patient scalar map with the corre-
sponding tissue type (WM, GM or mixed) and brain ROI (frontal, par-
ietal, temporal or occipital) value in the reference healthy distribution.
The mean and standard deviation values derived from the healthy
distribution of each single parameter in each ROI was considered as
being reasonably representative of the distribution, so that each de-
viation from “healthy tissue properties” may be calculated using the z-
score formula. Formally, we estimated the deviation as:
=Z I µv v
where ZV is the z-score for a single voxel, Iv is the intensity of voxel v, μ
is the mean of the healthy distribution over the 15 controls, and σ its
standard deviation. This expression of the z-score can be extended to a
more general approach taking inn consideration the different tissue
concentrations. In this case, the z-core per each voxel can be re-written
as:
= + ++ + + + +Z C I µ C I µ C I µC C C A B C( ) ( ) ( )( )v GM v GM WM v WM CSF v CSFGM WM CSF2 2 2 1/2
with
===
A C C Cov
B C C Cov
C C C Cov
2
2
2
GM WM GM WM
WM CSF WM CSF
GM CSF GM CSF
2 2
/
2
2 2
/
2
2 2
/
2
where Iv is the intensity of the voxel v in image and CGM, CWM, CCSF are
the concentration of GM, WM and CSF in the voxel v, respectively. μGM,
μWM, μCSF and σGM, σWM, σCSF are, respectively, the characteristic in-
tensities and variances of the GM, WM and CSF tissues in the ROI where
the voxel v belongs, while CovGM/WM, CovGM/CSF, CovWM/CSF are re-
spectively the covariances of the GM and WM, GM and CSF, WM and
CSF in the same region (see Fig. 2)
Fig. 6. Axial view of a T1 z-score map and a T1 map in RRMS patient 1 (top
row). Zoomed area showing the T1 z-score in one exemplary WM lesion (left)
and the corresponding T1 map (right). The lesion appears larger in the devia-
tion map with larger T1 z-scores in the center of the lesion and lower but still
≥3T1 z-scores in the lesion periphery/surrounding tissue.
Fig. 7. Axial view of a T1-zscore map over the corresponding T1 map (left) in patient 6 showing (A) a strong gradient in T1 z-scores within some WM lesions (T1
deviation z-score ranges from 10 in the core of the lesions to 2 in the edges) and (B) a moderate or minimal gradient in others (T1 z-score range left lesion: [2–4] and
right lesion: [2–3]). On the right side, the axial view of the corresponding T1 map.
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For the deep gray matter nuclei, we used the original z-score for-
mula (without concentrations, =Z I µv v ) as we considered that the
deep gray nuclei are composed by a single tissue characterized by a
mean and standard deviation values (μDGM and σDGM) calculated over
all voxels belonging to the deep gray nuclei of the group of controls.
2.4. Statistical analysis
Each deviation map quantifies the parametric variation re-
presentative of the changes occurring in an individual brain compared
to a distribution of healthy controls. Thus, in order to highlight both
focal and diffuse brain changes at baseline and two-years follow up, we
first computed the deviation maps over the four quantitative MR con-
trasts (T1, T2, T2* and MTR) for both RRMS subjects and the HC group.
Then, we analyzed the mean z-scores inside all voxels in all patients (i)
within the lesions, (ii) in the lesions vicinity as well as (iii) in the
normal appearing white matter (NAWM) and gray matter (NAGM) for
all parametric maps.
The classification of “pathological” z-scores was performed based on
a previous work (G. Bonnier, A. Roche and Romascano, et al. 2015),
where we MS lesions were classified into 3 groups as follows: (i) z very
low (z < −2), (ii) z very high (z > 2), and (iii) z close to the HC
distribution (−2≤ z≤2), considering the continuous distribution
(without distinct cluster) of lesions z-scores in each contrast: these
thresholds were chosen based on the fact that in a normal distribu-
tion>95% of the z-scores belongs to the interval [−2, 2] and that
values beyond this interval reflect significant differences in patients
compared to controls (P < .05).
For the longitudinal analysis, we computed difference maps (be-
tween the z-score maps obtained from the T1 map acquired at baseline
and the ones obtained at 2-years follow-up) to show focal and diffuse
brain changes.
3. Results
3.1. Healthy tissue distribution
The assessment of the distribution of the T1, T2, T2* and MTR maps
in our group of healthy controls validate the hypothesis of a reasonably
normal distribution of MRI intensities in all four lobes (see
Supplementary information, Section SI.3). Interestingly, the standard
deviation (σ) of the intensities in the voxels within the different lobes of
the healthy tissue distribution appear higher in GM than WM for all
qMRI metrics (σGM,T1= 160ms; σGM,T2= 16ms; σGM,T2⁎=22ms;
σGM,MTR=0.04ms; σWM,T1= 60ms; σWM,T2= 8ms; σWM,T2⁎=10ms;
σWM,MTR=0.02ms).
3.2. T1 deviation maps
The 4 healthy controls exhibited a much lower T1 deviation in WM
than patients in NAWM tissue (controls: zT1 0.04 ± 0.20 vs. RRMS
patients: zT1 0.50 ± 0.10 [mean ± standard deviation, SD]), Fig. 3A.
Compared to controls, the T1 deviation maps of RRMS patients
showed: (i) a strong increase in T1 z-score in lesions (zT1: 4.30 ± 1.60
[mean ± SD], Figs. 3B and 4), (ii) a moderate increase in T1 z-score in
the region surrounding the lesions (zT1: 0.90 ± 1.30 [mean ± SD]),
Figs. 3B and 6; and (iii) a lower increase in NAWM (zT1: 0.50 ± 0.10
[mean ± SD]) and NAGM tissue (zT1: 0.04 ± 0.09 [mean ± SD])
(Fig. 3A-B and 5).
Regarding the NA tissue, patients 1, 6 and 10 with a high LL but also
Fig. 8. Axial view of MTR, T2*, T2 and MTR z-score maps in controls 1 and 2 and patient 1 (high lesion load) and 2 (low lesion load).
G. Bonnier et al. NeuroImage: Clinical 21 (2019) 101607
8
Fig. 9. Barplots for mean (A) T2, (B) T2* and (C) MTR z-scores in RRMS NAWM (blue bar), lesions (red bar) and lesion surroundings (green bar). Whiskers extend to
the most extreme data points.
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patient 12 with a low LL (LL12= 0.40), showed a higher positive T1 z-
score in NA white matter (NAWM) (zT1 > 0.80) than other patients. All
patients showed a low z-scores in NAGM, with patients 1 and 13 have
the highest deviation (zT1 > 0.40) and patients 3 and 4 have the lowest
deviation (zT1 < 0.10). The highest z-scores were observed around and
between lesions (Fig. 5).
Also, MS lesions in the T1 deviation maps often appeared to be
larger than the manually segmented lesions (Fig. 6). This was most
probably due to areas of increased T1 relaxation times surrounding MS
lesions that were not perceived as lesion tissue by our neurologist and
radiologist experts.
Finally, the z-score map inside some large lesions revealed presence
of “core” of increased T1 relaxation time where the z-score is even
higher than in the rest of the lesion (Fig. 7).
3.3. Deviation map of T2, T2* and MTR
Compared to controls, patient's T2 deviation maps revealed a
moderate T2 relaxation time increase inside lesions (zT2= 1.76 ± 0.60
[mean ± standard deviation, SD]) and mild diffuse increases around
lesions (zT2= 0.70 ± 0.30 [mean ± SD]). T2* maps revealed also
slight increases inside lesions although lower than T2 (lesions:
zT2⁎=0.74 ± 0.36 [mean ± SD]) and no changes in lesion sur-
roundings (zT2⁎=0.30 ± 0.20 [mean ± SD]), while the MTR maps
showed a slight decrease inside the lesions (zMTR=−1.02 ± 0.60
[mean ± SD]) and no apparent diffuse changes around them
(zMTR=−0.20 ± 0.30 [mean ± SD]) (Figs. 8, 9). No differences
were observed between patients with high and low lesion loads.
The 4 healthy controls globally exhibited a similar T2, T2* and MTR
deviation than in NAWM and NAGM tissue in patients (T2 controls vs
patients NAWM [mean ± SD]: zT2–0.28 ± 0.07 vs zT2 0.21 ± 0.27;
NAGM [mean ± SD] zT2 – −0.18 ± 0.02; zT2 0.15 ± 0.; T2* controls
vs patients NAWM [mean ± SD]: zT2⁎- 0.14 ± 0.11 vs zT2⁎
0.22 ± 0.08; NAGM [mean ± SD]: zT2⁎– −0.11 ± 0.08; zT2⁎
0.04 ± 0.006; MTR controls vs patients NAWM [mean ± SD]: zMTR
−0.12 ± 0.17 vs zMTR 0.10 ± 0.21; NAGM [mean ± SD]: zMTR
0.03 ± 0.08; zMTR 0.06 ± 0.07).
3.4. Longitudinal analysis
In patients, some subcortical areas, predominant in the fronto-par-
ietal lobes, showed a concomitant increase in T1, T2, T2* z-scores and
Fig. 10. Axial difference between baseline (time point 1) and 2 years follow up (time point 2) of T1, T2, T2* and MTR z-score maps in patient 6 (top), patient 1
(middle) and control 2 (bottom). The difference maps give an overview of the changes occurring in the brain tissue of patients 6 and 1, and control 2.
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decrease of MTR z-scores over two years (Fig. 10A and C). In the lesion
periphery, some areas e exhibited a decrease in T1/T2 and slight de-
crease of T2* z-scores (Fig. 10A and B). Besides, other areas showed a
decrease in T1, T2 (T2*) and a concomitant increase in MTR (Fig. 10B).
4. Discussion
We have developed a novel approach to provide a personalized
quantification of brain damage using a voxel-wise comparison between
quantitative parameters of tissue integrity in a patient and the dis-
tribution of the same parameters in the same region and tissue in a
population of healthy controls.
To test the sensitivity and robustness of our method in the detection
of subtle pathological brain changes, we have applied it to a long-
itudinal dataset of early-stage RRMS patients, who were imaged using
four quantitative and semi-quantitative contrasts (T1, T2, T2*, MTR).
Those contrasts/metrics were chosen because their combination has
been previously proven to increase sensitivity and specificity to pa-
thological brain changes related to inflammation and degeneration
compared to single contrast/metric approaches (Bonnier et al., 2014;
Bonnier et al., 2015; Granziera et al., 2015; Romascano et al., 2015).
When both RRMS and control subjects were analyzed at baseline,
the proposed method was able to detect deviation from “normative
ranges” (computed as healthy tissue characteristic intensity obtained
from healthy subjects) for RRMS subjects, while no significant devia-
tions were found for our control test group. These differences were
especially remarkable within MS lesions and their vicinity but were also
sometimes evident in the remaining normal-appearing tissue.
As expected from previous group studies (Bonnier et al., 2014;
Bonnier et al., 2015; Deoni et al., 2008; Neema et al., 2007), T1 re-
laxation deviation maps computed in RRMS patients showed a global
increase in T1 relaxation time compared to the healthy control popu-
lation, which suggests the loss of tissue integrity (i.e. axonal, myelin
and cell damage) and/or extracellular water accumulation.
In MS lesions, T1 z-scores were in general increased and some le-
sions showed the peculiar microstructure reported in postmortem stu-
dies i.e. a gradient of damage from a central core with more pro-
nounced tissue loss (i.e. more prolonged T1 relaxation times compared
to healthy tissue) and areas surrounding it with less prolonged T1 re-
laxation times (Figs. 6, 7) (Bruck et al., 2002; Lassmann et al., 2001;
Lucchinetti and Bruck, 2004; Metz et al., 2014).
In the normal appearing tissue, the highest T1 z-scores were mea-
sured in the regions surrounding MS lesions, as previously reported
(Bonnier et al., 2014; Davies et al., 2007; Parry et al., 2002; Seewann
et al., 2009; Vrenken et al., 2010; West et al., 2014), (Figs. 3, 5). In-
creased T1 relaxation times point at a loss of tissue microstructural
damage and/or to an increase in iron content in the tissue (Bonnier
et al., 2017; Bonnier et al., 2014; Bonnier et al., 2015; Granziera C.,
2015), which are visible also in the absence of macroscopic global or
localized changes in brain volume (Bonnier et al., 2017; Bonnier et al.,
2014).
The remaining normal appearing tissue showed mild T1 increases
compared to the healthy population of references and interestingly,
NAGM showed lower deviation in T1 relaxation times compared to
healthy tissue than NAWM. This may be due to the presence of a lower
degree of tissue damage in GM than WM at early disease stages, which
is consistent with previous studies (Davies et al., 2007; Klaver et al.,
2013; Muhlau et al., 2013). Yet, this may also be due to higher PVE,
which induces a higher variability when computing the healthy GM
distribution compared to the WM.
As well, and as expected from previous literature (Parry et al., 2002,
2003; Rovira et al., 2013), the evaluation of T1 z-scores deviations in
MS patients showed a diffuse microstructural pathology that is not re-
lated to lesion load. Therefore, the personalized maps of tissue damage
– obtained with the proposed methodology- may help to better depict
the global damage provoked by MS disease, beyond the areas of focal
lesions.
On the other hand, the deviation maps obtained from T2, T2* and
MTR maps showed brain tissue alterations, which were located in the
same regions as the ones obtained from T1 maps (Fig. 8). Yet, while the
T2 and T2* deviation maps highlighted more diffuse changes in patient
white matter and gray matter tissue, the MTR deviation maps mainly
revealed focal changes in lesions (Fig. 8). Lesion and normal-appearing
tissue z-score deviations were positive for T2, T2* maps and negative
for MTR maps (Fig. 9), which is compatible with (i) tissue degenera-
tion/loss (in the presence of concomitant and strong increase in T1) or
(ii) inflammatory phenomena (in the presence of less pronounced in-
crease in T1 and/or concomitant increase in T2/T2*).
Nonetheless, the z-scores measured in T2, T2* and MTR maps were
less important than the ones revealed by T1 maps: this may be due to
the lower spatial resolution of the T2, T2* and MTR maps, which
translates in an increase of partial volume effect, but also to a higher
variability of the healthy distribution compared to the pathological
effect on the T2 and T2* relaxation times.
Longitudinal analysis of parametric deviation maps showed no
changes in control subjects but areas of z-score alterations in patients.
Specifically, in RRMS patients, we have evidenced regions with a con-
comitant increase in T1, T2, T2* z-scores and decrease of MTR z-scores,
a behavior suggesting brain tissue loss over time (Bonnier et al., 2017;
Bonnier et al., 2014; Deoni, 2011; Filippi and Agosta, 2007). Also, in
the lesion periphery, we could observe areas with decreased T1/T2 and
slight decrease of T2* indicating iron accumulation (Dusek et al.,
2013). Moreover, in other areas, we assessed longitudinal decrease in
T1, T2 (T2*) and a concomitant increase in MTR occurs, suggesting
remyelination/repair (Mallik et al., 2014), Fig. 10.
In summary, we have developed and assessed a method that pro-
vides a whole-brain personalized information of brain tissue damage
and showed its sensitivity to diffuse and focal changes in MS patients,
both cross-sectionally and longitudinally. One advantage of the pro-
posed method compared to conventional voxel-based morphometry is
that the maps are computed in patient space, therefore bypassing all
limitations of inter-subject registration (Klein et al., 2010). Another
advantage is the fact that it may be easily extended to other type of
images, provided that a large number of healthy subjects are also im-
aged with the same settings. Also, the proposed approach may be easily
extended to other neurological diseases since the applied metrics are
sensitive to neurodegenerative and neuroinflammatory changes also in
other neurological disorders such as mild cognitive impairment
(Granziera et al., 2015), neuroHIV infection (Granziera et al., 2013) and
migraine (Granziera et al., 2014).
The proposed method may still benefit of a number of targeted
improvements. Indeed, the healthy cohort of reference presently con-
sists of 65 and 15 subjects, who are reasonably but not perfectly re-
presentative of the healthy distribution of each metric. Because of this,
the presented results require confirmation using a larger reference co-
hort of healthy controls, which may reduce the variability of the in-
tensity distribution, increase the statistical power and improve sensi-
tivity of the comparison.
In addition, the T2 mapping method that we have applied in this
work models a mono-exponential T2 signal decay (Sumpft et al., 2011),
which may be violated by the presence of stimulated echoes. To mini-
mize this issue, we have discarded the first acquired echo (at
TE= 9ms). Despite that, however, the signal sampled with the re-
maining echoes (in the range from 20 to 170ms) may be still subjected
to model violations by the different T2 contributions in individual brain
voxels (MacKay, Whittal, et al. 1994, MacKay, Laule, et al. 2006, Barta,
et al. 2015). Indeed, for a precise measurement and quantification of
the different T2 components of the brain tissue, a much longer acqui-
sition and a more complex data modeling are necessary (MacKay,
Whittal, et al. 1994, MacKay, Laule, et al. 2006, Barta, et al. 2015).
Nevertheless, the applied T2 mapping measurement has shown high
sensitivity to brain pathological changes in neuroinflammatory and
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neurodegenerative diseases (Bonnier et al., 2017; Bonnier et al., 2014;
Bonnier et al., 2015; Granziera C., 2015) as well as high precision and
reproducibility (T2 variation of< 0.5ms were reported in scan-rescan
measurements and < 4ms across subjects) (Hilbert, et al. 2018) and
relatively short scan times, all characteristics that render it suitable for
clinical studies. Furthermore, the approach we propose uses the in-
formation provided by different contrasts and metrics (i.e. T1, T2, T2*
and MTR) to identify pathological changes in brain tissue micro-
structure and this is complementing - to a certain extent - the missing
information derived from a mono-exponential fitting of the T2 decay.
Lastly, future studies should also further explore the optimal cut-off
or range to detect neurodegenerative and inflammatory processes.
In conclusion, we have provided a method to calculate personalized
deviation maps in MRI, which may open new perspectives to comple-
ment and support clinical decisions. Future work will focus on in-
creasing the healthy control population, integrating automatic lesion
detection tools in the pipeline and in the identification of the optimal
threshold for pathological changes in each contrast.
Acknowledgements
This study was supported by the Swiss National Science Foundation,
Switzerland (under grants P2LAP3_164894 to GB, P2ELP2_172286 to
EF and PZ00P3 131914/1 to CG), the Swiss MS Society and the Societé
Académique Vaudoise in Switzerland. The funding sources had no role
in study design; in the collection, analysis, and interpretation of data; in
the writing of the report or in the decision to submit the paper for
publication.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.nicl.2018.11.017.
References
Arbabshirani, M.R., Plis, S., Sui, J., Calhoun, V.D., 2017. Single subject prediction of brain
disorders in neuroimaging: promises and pitfalls. NeuroImage 145, 137–165.
Aubert-Broche, B., Grova, C., Pike, G.B., Collins, D.L., 2009. Clustering of atlas-defined
cortical regions based on relaxation times and proton density. NeuroImage 47,
523–532.
Barta, R., Kalantari, S., Laule, C., Vavasour, I.M., MacKay, A.L., Michal, C.A., 2015 Oct.
Modeling T(1) and T(2) relaxation in bovine white matter. J. Magn. Reson. 259,
56–67. https://doi.org/10.1016/j.jmr.2015.08.001. Epub 2015 Aug 6.
Beeson, P.M., King, R.M., Bonakdarpour, B., Henry, M.L., Cho, H., Rapcsak, S.Z., 2011.
Positive effects of language treatment for the logopenic variant of primary pro-
gressive aphasia. J. Mol. Neurosci. 45, 724–736.
Bilgic, B., Gagoski, B.A., Cauley, S.F., Fan, A.P., Polimeni, J.R., Grant, P.E., Wald, L.L.,
Setsompop, K., 2015. Wave-CAIPI for highly accelerated 3D imaging. Magn. Reson.
Med. 73, 2152–2162.
Bonnier, G., Roche, A., Romascano, D., Simioni, S., Meskaldji, D., Rotzinger, D., Lin, Y.C.,
Menegaz, G., Schluep, M., Du Pasquier, R., Sumpf, T.J., Frahm, J., Thiran, J.P.,
Krueger, G., Granziera, C., 2014. Advanced MRI unravels the nature of tissue al-
terations in early multiple sclerosis. Ann. Clin. Transl. Neurol. 1, 423–432.
Bonnier, G., Roche, A., Romascano, D., Simioni, S., Meskaldji, D.E., Rotzinger, D., Lin,
Y.C., Menegaz, G., Schluep, M., Du Pasquier, R., Sumpf, T.J., Frahm, J., Thiran, J.P.,
Krueger, G., Granziera, C., 2015. Multicontrast MRI quantification of focal in-
flammation and degeneration in Multiple Sclerosis. Biomed. Res. Int. 2015, 569123.
Bonnier, G., Marechal, B., Fartaria, M.J., Falkowskiy, P., Marques, J.P., Simioni, S.,
Schluep, M., Du Pasquier, R., Thiran, J.P., Krueger, G., Granziera, C., 2017. The
combined quantification and interpretation of multiple quantitative magnetic
Resonance imaging metrics enlightens longitudinal changes compatible with brain
repair in relapsing-remitting Multiple Sclerosis patients. Front. Neurol. 8, 506.
Bookstein, F.L., 2001. "Voxel-based morphometry" should not be used with imperfectly
registered images. NeuroImage 14, 1454–1462.
Bruck, W., Lucchinetti, C., Lassmann, H., 2002. The pathology of primary progressive
multiple sclerosis. Mult. Scler. 8, 93–97.
Colliot, O., Bernasconi, N., Khalili, N., Antel, S.B., Naessens, V., Bernasconi, A., 2006.
Individual voxel-based analysis of gray matter in focal cortical dysplasia. NeuroImage
29, 162–171.
Davies, G.R., Hadjiprocopis, A., Altmann, D.R., Chard, D.T., Griffin, C.M., Rashid, W.,
Parker, G.J., Tofts, P.S., Kapoor, R., Thompson, A.J., Miller, D.H., 2007. Normal-
appearing grey and white matter T1 abnormality in early relapsing-remitting mul-
tiple sclerosis: a longitudinal study. Mult. Scler. 13, 169–177.
Deoni, S.C., 2011. Magnetic resonance relaxation and quantitative measurement in the
brain. Methods Mol. Biol. 711, 65–108.
Deoni, S.C., Williams, S.C., Jezzard, P., Suckling, J., Murphy, D.G., Jones, D.K., 2008.
Standardized structural magnetic resonance imaging in multicentre studies using
quantitative T1 and T2 imaging at 1.5 T. NeuroImage 40, 662–671.
Droby, A., Lukas, C., Schanzer, A., Spiwoks-Becker, I., Giorgio, A., Gold, R., De Stefano,
N., Kugel, H., Deppe, M., Wiendl, H., Meuth, S.G., Acker, T., Zipp, F., Deichmann, R.,
2015. A human post-mortem brain model for the standardization of multi-centre MRI
studies. NeuroImage 110, 11–21.
Dusek, P., Dezortova, M., Wuerfel, J., 2013. Imaging of iron. Int. Rev. Neurobiol. 110,
195–239.
Enzinger, C., Barkhof, F., Ciccarelli, O., Filippi, M., Kappos, L., Rocca, M.A., Ropele, S.,
Rovira, A., Schneider, T., de Stefano, N., Vrenken, H., Wheeler-Kingshott, C., Wuerfel,
J., Fazekas, F., Group, M.S., 2015. Nonconventional MRI and microstructural cerebral
changes in multiple sclerosis. Nat. Rev. Neurol. 11, 676–686.
Fartaria, M.J.R.A., Şorega, A., O'Brien, K., Krueger, G., Maréchal, B., Sati, P., Reich, D.S.,
Kober, T., Bach Cuadra, M., Granziera, C., 2017a. Automated Detection of White
Matter and Cortical Lesions in MP2RAGE at Ultra-High Fied using a Single Scan.
International Society for Magnetic Resonance Imaging, Honolulu, Hawaii.
Fartaria, M.J.R.A., Şorega, A., O'Brien, K., Krueger, G., Maréchal, B., Sati, P., Reich, D.S.,
Kober, T., Bach Cuadra, M., Granziera, C., 2017b. Automated Validation of
Automated Cortical and Subcortical Multiple Sclerosis Lesion Detection Using 7T
MP2RAGE Imaging. ECTRIMS.
Filippi, M., Agosta, F., 2007. Magnetization transfer MRI in multiple sclerosis. J.
Neuroimaging 17 (Suppl. 1), 22S–26S.
Georgiades, C.S., Itoh, R., Golay, X., van Zijl, P.C., Melhem, E.R., 2001. MR imaging of the
human brain at 1.5 T: regional variations in transverse relaxation rates in the cerebral
cortex. AJNR Am. J. Neuroradiol. 22, 1732–1737.
Granziera, C.S.T., 2015. Brain Inflammation, degeneration and plasticity in Multiple
Sclerosis. In: Toga, A.W. (Ed.), Brain Mapping: An Encyclopedic Reference, pp.
917–928.
Granziera, C., Daducci, A., Simioni, S., Cavassini, M., Roche, A., Meskaldji, D., Kober, T.,
Metral, M., Calmy, A., Helms, G., Hirschel, B., Lazeyras, F., Meuli, R., Krueger, G., Du
Pasquier, R.A., 2013. Micro-structural brain alterations in aviremic HIV+ patients
with minor neurocognitive disorders: a multi-contrast study at high field. PLoS One 8,
e72547.
Granziera, C., Daducci, A., Romascano, D., Roche, A., Helms, G., Krueger, G., Hadjikhani,
N., 2014. Structural abnormalities in the thalamus of migraineurs with aura: a
multiparametric study at 3 T. Hum. Brain Mapp. 35, 1461–1468.
Granziera, C., Daducci, A., Donati, A., Bonnier, G., Romascano, D., Roche, A., Bach
Cuadra, M., Schmitter, D., Kloppel, S., Meuli, R., von Gunten, A., Krueger, G., 2015. A
multi-contrast MRI study of microstructural brain damage in patients with mild
cognitive impairment. Neuroimage Clin. 8, 631–639.
Hasan, K.M., Walimuni, I.S., Abid, H., Datta, S., Wolinsky, J.S., Narayana, P.A., 2012.
Human brain atlas-based multimodal MRI analysis of volumetry, diffusimetry, re-
laxometry and lesion distribution in multiple sclerosis patients and healthy adult
controls: implications for understanding the pathogenesis of multiple sclerosis and
consolidation of quantitative MRI results in MS. J. Neurol. Sci. 313, 99–109.
Helms, G., 2015. Tissue properties from quantitative MRI. In: Toga, A.W. (Ed.), Brain
Mapping: An Encyclopedic Reference. Elsevier, pp. 287–294.
Helms, G., Hagberg, G.E., 2009. In vivo quantification of the bound pool T1 in human
white matter using the binary spin-bath model of progressive magnetization transfer
saturation. Phys. Med. Biol. 54, N529–N540.
Hilbert, T., Sumpf, T.J., Weiland, E., Frahm, J., Thiran, J.P., Meuli, R., Kober, T., Krueger,
G., 2018. Accelerated T2 mapping combining parallel MRI and model-based re-
construction: GRAPPATINI. J. Magn. Reson. Imaging. 48 (2), 359–368.
Klaver, R., De Vries, H.E., Schenk, G.J., Geurts, J.J., 2013. Grey matter damage in mul-
tiple sclerosis: a pathology perspective. Prion 7, 66–75.
Klein, S., Staring, M., Murphy, K., Viergever, M.A., Pluim, J.P., 2010. Elastix: a toolbox for
intensity-based medical image registration. IEEE Trans. Med. Imaging 29, 196–205.
Kober, T., Granziera, C., Ribes, D., Browaeys, P., Schluep, M., Meuli, R., Frackowiak, R.,
Gruetter, R., Krueger, G., 2012. MP2RAGE multiple sclerosis magnetic resonance
imaging at 3 T. Investig. Radiol. 47, 346–352.
Kruggel, F., Masaki, F., Solodkin, A., Alzheimer's Disease Neuroimaging, I, 2017. Analysis
of longitudinal diffusion-weighted images in healthy and pathological aging: an ADNI
study. J. Neurosci. Methods 278, 101–115.
Lassmann, H., Bruck, W., Lucchinetti, C., 2001. Heterogeneity of multiple sclerosis pa-
thogenesis: implications for diagnosis and therapy. Trends Mol. Med. 7, 115–121.
Lucchinetti, C., Bruck, W., 2004. The pathology of primary progressive multiple sclerosis.
Mult. Scler. 10 (Suppl. 1), S23–S30.
MacKay, A., Whittall, K., Adler, J., Li, D., Paty, D., Graeb, D., 1994 Jun. In vivo visua-
lization of myelin water in brain magnetic resonance. Magn. Reson. Med. 31 (6),
673–677.
MacKay, A., Laule, C., Vavasour, I., Bjarnason, T., Kolind, S., Mädler, B., 2006 May May.
Insights into brain microstructure from the T2 distribution. Magn. Reson. Imaging. 24
(4), 515–525 Epub 2006 Mar 20.
Mallik, S., Samson, R.S., Wheeler-Kingshott, C.A., Miller, D.H., 2014. Imaging outcomes
for trials of remyelination in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 85,
1396–1404.
Marques, J.P., Kober, T., Krueger, G., van der Zwaag, W., Van de Moortele, P.F., Gruetter,
R., 2010. MP2RAGE, a self bias-field corrected sequence for improved segmentation
and T1-mapping at high field. NeuroImage 49, 1271–1281.
Metere, R., Kober, T., Moller, H.E., Schafer, A., 2017. Simultaneous quantitative MRI
mapping of T1, T2* and magnetic susceptibility with multi-echo MP2RAGE. PLoS
One 12, e0169265.
Metz, I., Weigand, S.D., Popescu, B.F., Frischer, J.M., Parisi, J.E., Guo, Y., Lassmann, H.,
Bruck, W., Lucchinetti, C.F., 2014. Pathologic heterogeneity persists in early active
G. Bonnier et al. NeuroImage: Clinical 21 (2019) 101607
12
multiple sclerosis lesions. Ann. Neurol. 75, 728–738.
Meyer, S., Mueller, K., Stuke, K., Bisenius, S., Diehl-Schmid, J., Jessen, F., Kassubek, J.,
Kornhuber, J., Ludolph, A.C., Prudlo, J., Schneider, A., Schuemberg, K., Yakushev, I.,
Otto, M., Schroeter, M.L., Group, F.T.S, 2017. Predicting behavioral variant fronto-
temporal dementia with pattern classification in multi-center structural MRI data.
Neuroimage Clin. 14, 656–662.
Muhlau, M., Wohlschlager, A.M., Gaser, C., Valet, M., Weindl, A., Nunnemann, S.,
Peinemann, A., Etgen, T., Ilg, R., 2009. Voxel-based morphometry in individual pa-
tients: a pilot study in early Huntington disease. AJNR Am. J. Neuroradiol. 30,
539–543.
Muhlau, M., Buck, D., Forschler, A., Boucard, C.C., Arsic, M., Schmidt, P., Gaser, C.,
Berthele, A., Hoshi, M., Jochim, A., Kronsbein, H., Zimmer, C., Hemmer, B., Ilg, R.,
2013. White-matter lesions drive deep gray-matter atrophy in early multiple
sclerosis: support from structural MRI. Mult. Scler. 19, 1485–1492.
Neema, M., Stankiewicz, J., Arora, A., Dandamudi, V.S., Batt, C.E., Guss, Z.D., Al-
Sabbagh, A., Bakshi, R., 2007. T1- and T2-based MRI measures of diffuse gray matter
and white matter damage in patients with multiple sclerosis. J. Neuroimaging 17
(Suppl. 1), 16S–21S.
Parry, A., Clare, S., Jenkinson, M., Smith, S., Palace, J., Matthews, P.M., 2002. White
matter and lesion T1 relaxation times increase in parallel and correlate with disability
in Multiple sclerosis. J. Neurol. 249, 1279–1286.
Parry, A., Clare, S., Jenkinson, M., Smith, S., Palace, J., Matthews, P.M., 2003. MRI brain
T1 relaxation time changes in MS patients increase over time in both the white matter
and the cortex. J. Neuroimaging 13, 234–239.
Polman, C., Reingold, S., Banwell, B., Clanet, M., Cohen, J., Filippi, M., Fujihara, H.,
Havrdova, E., Hutchinsom, M., Kappos, L., Lublin, F., Montalban, X., O'Connor, P.,
Sandberg-Wollheim, M., Thompson, A., Waubant, E., Weinshenker, B., Wolinsky, J.,
2011. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald cri-
teria. Ann. Neurol. 69, 292–302.
Roche, A., Forbes, F., Alzheimer's Disease Neuroimaging, I, 2014. Partial volume esti-
mation in brain MRI revisited. Med. Image Comput. Comput. Assist. Interv. 17,
771–778.
Romascano, D., Meskaldji, D.E., Bonnier, G., Simioni, S., Rotzinger, D., Lin, Y.C.,
Menegaz, G., Roche, A., Schluep, M., Pasquier, R.D., Richiardi, J., Van De Ville, D.,
Daducci, A., Sumpf, T., Fraham, J., Thiran, J.P., Krueger, G., Granziera, C., 2015.
Multicontrast connectometry: a new tool to assess cerebellum alterations in early
relapsing-remitting multiple sclerosis. Hum. Brain Mapp. 36, 1609–1619.
Rovira, A., Auger, C., Alonso, J., 2013. Magnetic resonance monitoring of lesion evolution
in multiple sclerosis. Ther. Adv. Neurol. Disord. 6, 298–310.
Sajjadi, S.A., Acosta-Cabronero, J., Patterson, K., Diaz-De-Grenu, L.Z., Williams, G.B.,
Nestor, P.J., 2013. Diffusion tensor magnetic resonance imaging for single subject
diagnosis in neurodegenerative diseases. Brain 136, 2253–2261.
Scarpazza, C., Sartori, G., De Simone, M.S., Mechelli, A., 2013. When the single matters
more than the group: very high false positive rates in single case Voxel based
Morphometry. NeuroImage 70, 175–188.
Schmitter, D., Roche, A., Marechal, B., Ribes, D., Abdulkadir, A., Bach-Cuadra, M.,
Daducci, A., Granziera, C., Kloppel, S., Maeder, P., Meuli, R., Krueger, G., Alzheimer's
Disease Neuroimaging, I, 2015. An evaluation of volume-based morphometry for
prediction of mild cognitive impairment and Alzheimer's disease. Neuroimage Clin. 7,
7–17.
Seewann, A., Vrenken, H., van der Valk, P., Blezer, E.L., Knol, D.L., Castelijns, J.A.,
Polman, C.H., Pouwels, P.J., Barkhof, F., Geurts, J.J., 2009. Diffusely abnormal white
matter in chronic Multiple sclerosis: imaging and histopathologic analysis. Arch.
Neurol. 66, 601–609.
Stephan, K.E., Schlagenhauf, F., Huys, Q.J.M., Raman, S., Aponte, E.A., Brodersen, K.H.,
Rigoux, L., Moran, R.J., Daunizeau, J., Dolan, R.J., Friston, K.J., Heinz, A., 2017.
Computational neuroimaging strategies for single patient predictions. NeuroImage
145, 180–199.
Sumpf, T.J., Uecker, M., Boretius, S., Frahm, J., 2011. Model-based nonlinear inverse
reconstruction for T2 mapping using highly undersampled spin-echo MRI. J. Magn.
Reson. Imaging 34, 420–428.
Vrenken, H., Seewann, A., Knol, D.L., Polman, C.H., Barkhof, F., Geurts, J.J., 2010.
Diffusely abnormal white matter in progressive multiple sclerosis: in vivo quantita-
tive MR imaging characterization and comparison between disease types. AJNR Am.
J. Neuroradiol. 31, 541–548.
Wansapura, J.P., Holland, S.K., Dunn, R.S., Ball Jr., W.S., 1999. NMR relaxation times in
the human brain at 30 tesla. J. Magn. Reson. Imaging 9, 531–538.
West, J., Aalto, A., Tisell, A., Leinhard, O.D., Landtblom, A.M., Smedby, O., Lundberg, P.,
2014. Normal appearing and diffusely abnormal white matter in patients with mul-
tiple sclerosis assessed with quantitative MR. PLoS One 9, e95161.
G. Bonnier et al. NeuroImage: Clinical 21 (2019) 101607
13
